June 2017
WHILE A SMALL NUMBER OF PEOPLE ARE SUFFERING FROM A SINGLE RARE DISEASE, 350 MILLION PEOPLE WORLDWIDE ARE SUFFERING FROM RARE DISEASES. 3rd most populous country 50% of affected are children 30% will not see their 5th birthday 7.6 years to diagnose in US 80% OF RARE DISEASES ARE CAUSED BY MUTATIONS IN OUR GENOME.
RARE DISEASE COMPANY As one of the largest and most diversified genetic testing companies we are dedicated to transforming the worldwide science of genetic data into solutions and hope for patients and their families by answering two very important questions. 1. How to identify patients with a specific rare disease as early as possible? 2. What is the best treatment for these patients?
CENTOGENE Management CEO and CFO Prof. Arndt Rolfs, MD CEO, Founder Professor for Neurology, University of Rostock Consultant for international biotech and industrial companies Principal investigator of multiple international multicenter studies in the area of rare diseases > 220 peer-reviewed papers Richard Stoffelen CFO Certified Public Accountant Nearly 20 years of experience in Big 4 Accounting firm Head of Internal Audit at Holcim Group Services Experienced in IPOs and Bond issuances
CENTOGENE HIGHLIGHTS Established Global Footprint with Strong Historical Growth Growth 2010-2016 by revenue (CAGR): > 40% Headquarters Germany Affiliations Delhi, Dubai, Vienna Cumulative Revenue > EUR 100 mill Outstanding historical growth In EUR million Receiving samples from over 110 countries
CENTOGENE HIGHLIGHTS Building the Definite Knowledge Base in Rare Disease ~ 300 employees Clients: > 16,000 Number of test in 2016 ~120,000 Academics employed: ~70% CentoMD Identified Individuals: ~120,000 Number of Genes in the Test Portfolio: >3,100
CENTOGENE s Business Model A self-amplifying value cycle building the Definite Knowledge Base in Rare Disease Knowledge Products Diagnostic s Pharma Collaborations Data, Information, Knowledge
Diagnostics The Foundation of Genetic Information and Entrance to Higher Value Added Solutions Knowledge Products Diagnostics Pharma Collaborations Samples Collection Sequencing Bioinformatics & Interpretation Medical Report Creation
CentoCard and CentoPortal Simple-to-use Logistics solution to Physicians and Patients SENDING SAMPLES AS POSTCARDS ORDER AND ACCESS TEST REPORTS AT ANY TIME FROM ANYWHERE
Pharmaceutical Collaborations High margin solutions monetized gained from Diagnostics services Knowledge Products Diagnostics Pharma Collaborations Data Knowledge CENTOGENE s is able to translate its Strengths into the needs of Pharmceutical companies and CROs by assisting them to: Patients screening and finding Clincial trails and marketable phases Biomarker development Trial design and planning Support clinical trial phases Companion Diagnostics Precision medicine supporting reimbusement Increase rare disease awareness from collaborational partnership and co-marketing efforts
EXAMPLES of BIOMARKER DEVELOPMENT at CENTOGENE
Knowledge Products Connecting knowledge between genotype and phenotype Knowledge Data Knowledge Products Diagnostics Pharma Collaborations Genetic Variants Clinical Symptoms Knowledge Data
CentoMD 3.3 - LARGEST MUTATION DATABASE FOF RARE DISEASES, FULLY CURATED, BASED ON CLINICAL AND GENETIC DATA CentoMD is our proof-of-concept for digital products that meet FDA s medical device regulation > 3,300 > 790 Mio > 4.0 Mio Centogene is a world-wide first mover in FDA-approved medical databases Genotype-Phenotype Phenotype-Genotype
CentoCloud offering Unique High Quality Bioinformatic Services Preparation Sequencing Processing Interpretation Communication Sequencing Billing Customer Customer Panel design & generation Sequencing Bioinformatic pipeline Technical & medical interpretation Creating medical report
CENTOGENE Accelerated growth by combination of new technologies
OUR BUSINESS MODEL IS SELF AMPLIFYING EVERY STEP OF THE WAY
THANK YOU